Effect of amiodarone hydrochloride tablets combined with potassium magnesium aspartate on hemodynamics and cardiac function in patients with coronary heart disease and arrhythmia

Purpose: To investigate the effects of amiodarone hydrochloride tablets combined with potassium magnesium aspartate on hemodynamics and cardiac function in coronary heart disease (CHD) patients with arrhythmia. Methods: In this retrospective research, a total of 110 CHD and arrhythmia patients on admission at Jiaozhou Central Hospital of Qingdao from June 2020 to June 2022 were randomly but equally divided into control group (CG) treated with propafenone hydrochloride tablets, and study group (SG) treated with a combination of amiodarone hydrochloride tablets and potassium magnesium aspartate. Clinical efficacy of the treatment types as well as the number of premature ventricular contractions (PVC), QTc interval and heart rate (HR) of the patients were monitored to determine left ventricular end-diastolic diameter (LVEDD), left ventricular end-systolic diameter (LVESD), and cardiac index (CI). Fibrinogen levels, plasma viscosity and hematocrit of the patients were also assessed. Results: The total effectiveness/efficacy of treatment in SG was 92.73 %, which was significantly higher than the corresponding CG value of 76.36 % (p < 0.05). Relative to CG, PVC and HR in SG were significantly lower, while QTc interval was significantly higher. The levels of LVESD and LVEDD were significantly lower in SG than in CG, while CI level was significantly higher. However, fibrinogen, plasma viscosity and hematocrit values were significantly lower in SG than in CG (p < 0.05). Conclusion: When administered along with potassium magnesium aspartate in the treatment of CHD and arrhythmia, amiodarone hydrochloride tablets enhances clinical efficacy and improves electrocardiograph index, hemodynamics and cardiac function. Nonetheless, there is need for expanded clinical trials before the use of this treatment strategy in clinical practice.